Division of Cardiology, Department of Medical Sciences, AOU Città della Salute e della Scienza, University of Turin, Turin, Italy.
Centro Cardiologico Monzino, IRCCS, Milan, Italy.
Eur J Heart Fail. 2020 Feb;22(2):330-337. doi: 10.1002/ejhf.1698. Epub 2019 Dec 20.
The aim of the present study was to investigate the impact of aspirin on prognosis in takotsubo syndrome (TTS).
Patients from the International Takotsubo (InterTAK) Registry were categorized into two groups based on aspirin prescription at discharge. A comparison of clinical outcomes between groups was performed using an adjusted analysis with propensity score (PS) stratification; results from the unadjusted analysis were also reported to note the effect of the PS adjustment. Major adverse cardiac and cerebrovascular events (MACCE: a composite of death, myocardial infarction, TTS recurrence, stroke or transient ischaemic attack) were assessed at 30-day and 5-year follow-up. A total of 1533 TTS patients with known status regarding aspirin prescription at discharge were included. According to the adjusted analysis based on PS stratification, aspirin was not associated with a lower hazard of MACCE at 30-day [hazard ratio (HR) 1.24, 95% confidence interval (CI) 0.50-3.04, P = 0.64] or 5-year follow-up (HR 1.11, 95% CI 0.78-1.58, P = 0.58). These results were confirmed by sensitivity analyses performed with alternative PS-based methods, i.e. covariate adjustment and inverse probability of treatment weighting.
In the present study, no association was found between aspirin use in TTS patients and a reduced risk of MACCE at 30-day and 5-year follow-up. These findings should be confirmed in adequately powered randomized controlled trials. ClinicalTrials.gov Identifier: NCT01947621.
本研究旨在探讨阿司匹林对扩张型心肌病(TTS)预后的影响。
根据出院时是否开具阿司匹林,将国际扩张型心肌病(InterTAK)登记处的患者分为两组。使用倾向评分(PS)分层的调整分析比较两组的临床结局;还报告了未调整分析的结果,以注意 PS 调整的效果。在 30 天和 5 年随访时评估主要不良心脑血管事件(MACCE:死亡、心肌梗死、TTS 复发、卒中和短暂性脑缺血发作的复合事件)。共纳入 1533 例已知出院时阿司匹林使用情况的 TTS 患者。根据基于 PS 分层的调整分析,阿司匹林与 30 天内 MACCE 的风险降低无关[风险比(HR)1.24,95%置信区间(CI)0.50-3.04,P=0.64]或 5 年随访(HR 1.11,95% CI 0.78-1.58,P=0.58)。这些结果通过使用替代 PS 方法(即协变量调整和治疗反概率加权)进行的敏感性分析得到证实。
本研究未发现 TTS 患者使用阿司匹林与 30 天和 5 年随访时 MACCE 风险降低相关。这些发现应在充分有力的随机对照试验中得到证实。ClinicalTrials.gov 标识符:NCT01947621。